

24. **Buyse G, Waldeck K, Verpoorten C, et al.** Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. *J Urol* 1998; 160(3 Pt 1): 892–896.
25. **Cheng T, Shuang W-b, Jia D-d, et al.** Efficacy and safety of onabotulinumtoxin A in patients with neurogenic detrusor overactivity: A systematic review and meta-analysis of randomized controlled trials. *PLOS ONE* 2016; 11(7): e0159307.
26. **De Ridder D, Van Poppel H, Baert L, et al.** From time dependent intermittent selfcatheterisation to volume dependent selfcatheterisation in Multiple Sclerosis using the PCI 5000 Bladdermanager(R). *Spinal cord* 1997; 35: 613–616.
27. **Giannantoni A, Scivoletto G, Di Stasi SM, et al.** Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. *Neurourol Urodyn* 1998; 17(2): 89–98.
28. **Wall BM, Dmochowski RR, Malecha M, et al.** Inducible nitric oxide synthase in the bladder of spinal cord injured patients with a chronic indwelling urinary catheter. *J Urol* 2001; 165(5): 1457–1461.
29. **Ozawa H, Uematsu K, Ohmori H, et al.** Long-term usefulness and safety of the contemporary balloon catheter. *Nihon Hinyokika Gakkai Zasshi*. 2005; 96(5): 541–547.
30. **Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M, et al.** Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. *J Urol* 2000; 164(5): 1476–1480.
31. **Zachoval R, Pitha J, Medova E, et al.** Augmentation cystoplasty in patients with multiple sclerosis. *Urol Int* 2003; 70(1): 21–26.
32. **Phé V, Pakzad M, Curtis C, et al.** Urinary tract infections in multiple sclerosis. *Mult Scler* 2016; 22(7): 855–861.
33. **Marrie RA, Elliott L, Marriott J, et al.** Dramatically changing rates and reasons for hospitalization in multiple sclerosis. *Neurology* 2014; 83(10): 929–937.
34. **Mahadeva A, Tanasescu R, Gran B.** Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. *Am J Clin Exp Immunol* 2014; 3(1): 57–67.
35. **Sibley WA, Bamford CR, Clark K.** Clinical viral infections and multiple sclerosis. *Lancet* 1985; 1(8441): 1313–1315.
36. **Winkelmann A, Loebermann M, Reisinger EC, et al.** Multiple sclerosis treatment and infectious issues: update 2013. *Clin Exp Immunol* 2014; 175(3): 425–438.
37. **Guo ZN, He SY, Zhang HL, et al.** Multiple sclerosis and sexual dysfunction. *Asian J Androl* 2012; 14(4):530–535.
38. **Shridharani AN, Brant WO.** The treatment of erectile dysfunction in patients with neurogenic disease. *Transl Androl Urol* 2016; 5(1): 88–101.
39. **Foley FW, LaRocca NG, Sanders AS, Zemon V.** Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. *Mult Scler* 2001; 7(6): 417–421.
40. **Fragala E, Russo GI, Di Rosa A, et al.** Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. *Eur J Neurol* 2015; 22(3): 485–492.
41. **Lombardi G, Musco S, Wyndaele JJ, et al.** Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. *Spinal Cord* 2015; 53(12): 849–854.
42. **Cardenas DD, Ditunno JF, Graziani V, et al.** Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. *Spinal Cord* 2014; 52(1): 70–76.
43. **Kessler TM, Fowler CJ, Panicker JN.** Sexual dysfunction in multiple sclerosis. *Expert Rev Neurother* 2009; 9(3): 341–350.